World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)

CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Potential Market Opportunity
Issues and Trends Affecting Market
Leading Companies

CHAPTER TWO: INTRODUCTION
Global Pharmaceutical Market
Pharmaceutical Research & Development Overview
Clinical Trial Costs

CHAPTER THREE: ISSUES AND TRENDS
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity Legislation
Aging Population
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
The Role of Contract Research Organizations
Sustainability in a changing Pharmaceutical Industry

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Introduction
Pfizer, Inc./Wyeth (merged in 2009)
Overview
Financial Performance and Investments
Late Stage Pipeline
Merck & Co., Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Novartis AG
Overview
Financial Performance and Investments
Late Stage Pipeline
Roche Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
Sanofi-Aventis
Overview
Financial Performance and Investments
Late Stage Pipeline
AstraZeneca plc
Overview
Financial Performance and Investments
Late Stage Pipeline
GlaxoSmithKline plc
Overview
Financial Performance and Investments
Late Stage Pipeline
Johnson & Johnson
Overview
Financial Performance and Investments
Late Stage Pipeline
Eli Lilly & Company
Overview
Financial Performance and Investments
Late Stage Pipeline
Bristol-Myers Squibb Company
Overview
Financial Performance and Investments
Late Stage Pipeline
Abbott Laboratories
Overview
Financial Performance and Investments
Late Stage Pipeline
Takeda Pharmaceutical Co., Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
Bayer AG
Overview
Financial Performance and Investments
Late Stage Pipeline
Amgen, Inc.
Overview
Financial Performance and Investments
Late Stage Pipeline
Boehringer Ingelheim GmbH
Overview
Financial Performance and Investments
Late Stage Pipeline
TEVA Pharmaceutical Industries, Ltd.
Overview
Financial Performance and Investments
Late Stage Pipeline
Astellas
Overview
Financial Performance and Investments
Late Stage Pipeline
Daiichi Sankyo
Overview
Financial Performance and Investments
Late Stage Pipeline
Novo Nordisk
Overview
Financial Performance and Investments
Late Stage Pipeline
Eisai
Overview
Financial Performance and Investments
Late Stage Pipeline

CHAPTER FIVE: COMPANIES OF INTEREST
Introduction
Otsuka
Late Stage Pipeline
Merck KGaA
Late Stage Pipeline
Gilead Sciences
Late Stage Pipeline
Mylan
Pipeline
Baxter International
Late Stage Pipeline
Chugai Pharmaceutical Company, Ltd.
Late Stage Pipeline
Mitsubishi Tanabe
Late Stage Pipeline
Servier, Les Laboratories
Pipeline
UCB SA
Late Stage Pipeline
Allergan
Late Stage Pipeline
Forest Laboratories
Late Stage Pipeline
Nycomed International
Late Stage Pipeline
Genzyme Corporation
Late Stage Pipeline
Biogen Idec
Late Stage Pipeline
Hospira
Late Stage Pipeline
Watson
Pipeline
CSL Limited
Late Stage Pipeline
Alcon
Late Stage Pipeline
Shire
Late Stage Pipeline
Celgene Corporation
Late Stage Pipeline
Lundbeck
Late Stage Pipeline
Shionogi & Co., Ltd.
Late Stage Pipeline
Menarini Group
Late Stage Pipeline
Dainippon Sumitomo Pharma, Co., Ltd.
Late Stage Pipeline
Cephalon
Late Stage Pipeline
Actelion
Late Stage Pipeline
Procter & Gamble
Endo Pharmaceuticals
Late Stage Pipeline
Ono Pharmaceutical Co.
Late Stage Pipeline
Purdue Pharma
Late Stage Pipeline

CHAPTER SIX: MARKET FORECAST
Overview
Company Analysis
Pipeline Snapshot: Top 50 Companies
Current Market Value
Market Forecast

CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET
Biopharmaceutical Companies
Biopharmaceutical Market Forecast

APPENDIX: LIST OF COMPANIES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)
Figure 1-1: Global Pharmaceutical Market Research and Development Impact by Therapeutic Segment, 2015—based on late stage development projects evaluated

CHAPTER TWO: INTRODUCTION
Table 2-1: Phases of Clinical Drug Development
Table 2-2: Components of a Clinical Trial

CHAPTER THREE: ISSUES AND TRENDS
Table 3-1: International Population Trend Age 65+
Figure 3-1: International Population Trend Age 65+
Table 3-2: United States Population Trend Age 65+
Figure 3-2: International Population Trend Age 65+
Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions
Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics
Figure 3-3: Drug Development Cost Progression
Table 3-5: Total Industry R&D Spending 2004-2009
Figure 3-4: Total Industry R&D Spending 2004-2009

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS
Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2009 Sales (millions)
Table 4-2: Pfizer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-1: Pfizer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-3: Pfizer’s Late Stage Product Pipeline
Figure 4-2: Pfizer’s Late Stage Product Pipeline by Therapeutic Area
Table 4-4: Merck’s* Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-3: Merck’s* Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-5: Merck & Co.’s Late Stage Product Pipeline
Figure 4-4: Merck’s Late Stage Product Pipeline by Therapeutic Area
Table 4-6: Novartis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-5: Novartis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-7: Novartis’ Late Stage Product Pipeline
Figure 4-6: Novartis’ Late Stage Product Pipeline by Therapeutic Area
Table 4-8: Roche’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-7: Roche’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-9: Roche’s Late Stage Product Pipeline
Figure 4-8: Roche’s Late Stage Product Pipeline by Therapeutic Area
Table 4-10: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-9: Sanofi-Aventis’ Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-11: Sanofi-Aventis’ Late Stage Product Pipeline
Figure 4-10: Sanofi Aventis’ Late Stage Product Pipeline by Therapeutic Area
Table 4-12: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-11: AstraZeneca’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-13: AstraZeneca’s Late Stage Product Pipeline
Figure 4-12: AstraZeneca’ Late Stage Product Pipeline by Therapeutic Area
Table 4-14: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-13: GlaxoSmithKline’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-15: GlaxoSmithKline’s Late Stage Product Pipeline
Figure 4-14: GlaxoSmithKline’s Late Stage Product Pipeline by Therapeutic Area
Table 4-16: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-15: Johnson & Johnson’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-17: Johnson & Johnson’s Late Stage Product Pipeline
Figure 4-16: Johnson & Johnson’s Late Stage Product Pipeline by Therapeutic Area
Table 4-18: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-17: Eli Lilly’s Total Company Revenue and R&D Spending 2007-2009
Table 4-19: Eli Lilly’s Late Stage Product Pipeline
Figure 4-18: Eli Lilly & Co.’s Late Stage Product Pipeline by Therapeutic Area
Table 4-20: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-19: Bristol-Myers Squibb’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-21: Bristol-Myers Squibb’s Late Stage Product Pipeline
Figure 4-20: Bristol-Myers’ Late Stage Product Pipeline by Therapeutic Area
Table 4-22: Abbott’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-21: Abbott’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-23: Abbott’s Late Stage Product Pipeline
Figure 4-22: Abbott’s Late Stage Product Pipeline by Therapeutic Area
Table 4-24: Takeda’s Total Company Revenue* and R&D Spending 2007-2009 (Millions)
Figure 4-23: Takeda’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-25: Takeda Pharmaceutical’s Late Stage Product Pipeline
Figure 4-24: Takeda Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
Table 4-26: Bayer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-25: Bayer’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-27: Bayer’s Late Stage Product Pipeline
Figure 4-26: Bayers’ Late Stage Product Pipeline by Therapeutic Area
Table 4-28: Amgen’s Total Company Revenue and R&D Spending 2007-2009 (Millions) Figure 4-27: Amgen’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-29: Amgen’s Late Stage Product Pipeline
Figure 4-28: Amgen’s Late Stage Product Pipeline by Therapeutic Area
Table 4-30: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-29: Boehringer Ingelheim’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-31: Boehringer Ingelheim’s Late Stage Product Pipeline
Figure 4-30: Boehringer Ingelheim’s Late Stage Product Pipeline by Therapeutic Area
Table 4-32: TEVA’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Figure 4-31: TEVA’s Total Company Revenue and R&D Spending 2007-2009 (Millions)
Table 4-33: TEVA’s Late Stage Product Pipeline Figure 4-32: TEVA’s Late Stage Product Pipeline by Therapeutic Area
Table 4-34: Astellas’ Total Company Revenue and R&D Spending 2007-2009 (millions)
Figure 4-33: Astellas’ Total Company Revenue and R&D Spending 2007-2009 (millions)
Table 4-35: Astellas’ Late Stage Product Pipeline
Figure 4-34: Astellas’ Late Stage Product Pipeline by Therapeutic Area
Table 4-36: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions)
Figure 4-35: Daiichi Sankyo’s Total Company Revenue and R&D Spending 2007-2009 (millions)
Table 4-37: Daiichi Sankyo’s Late Stage Product Pipeline
Figure 4-36: Daiichi Sankyo’s Late Stage Product Pipeline by Therapeutic Area
Table 4-38: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2009 (millions)
Figure 4-37: Novo Nordisk’s Total Company Revenue and R&D Spending 2007-2009 (millions)
Table 4-39: Novo Nordisk’s Late Stage Product Pipeline
Figure 4-38: Novo Nordisk’s Late Stage Product Pipeline by Therapeutic Area
Table 4-40: Eisai’s Total Company Revenue and R&D Spending 2007-2009 (Thousands)
Figure 4-39: Eisai’s Total Company Revenue and R&D Spending 2007-2009
Table 4-41: Eisai’s Late Stage Product Pipeline
Figure 4-40: Eisai’s Late Stage Product Pipeline by Therapeutic Area

CHAPTER FIVE: COMPANIES OF INTEREST
Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2009 Sales
Table 5-2: Otsuka Pharmaceutical’s Late Stage Product Pipeline
Figure 5-1: Otsuka Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
Table 5-3: Merck KGaA’s Late Stage Product Pipeline
Figure 5-2: Merck KGaA’s Late Stage Product Pipeline by Therapeutic Area
Table 5-4: Gilead Sciences’ Late Stage Product Pipeline
Figure 5-3: Gilead Sciences’ Late Stage Product Pipeline by Therapeutic Area
Table 5-5: Baxter International’s Late Stage Product Pipeline
Figure 5-4: Baxter International’s Late Stage Product Pipeline by Therapeutic Area
Table 5-6: Chugai Pharmaceutical’s Late Stage Product Pipeline
Figure 5-5: Chugai’s Late Stage Product Pipeline by Therapeutic Area
Table 5-7: Mitsubishi Tanabe’s Late Stage Product Pipeline
Figure 5-6: Mitsubishi Tanabe’s Late Stage Product Pipeline by Therapeutic Area
Table 5-8: UCB Pharma’s Late Stage Product Pipeline
Figure 5-7: UCB’s Late Stage Product Pipeline by Therapeutic Area
Table 5-9: Allergan’s Late Stage Product Pipeline
Figure 5-8: Allergan’s Late Stage Product Pipeline by Therapeutic Area
Table 5-10: Forest Laboratories’ Late Stage Product Pipeline
Figure 5-9: Forest Laboratories’ Late Stage Product Pipeline by Therapeutic Area
Table 5-11: Nycomed’s Late Stage Product Pipeline
Figure 5-10: Nycomed’s Late Stage Product Pipeline by Therapeutic Area
Table 5-12: Genzyme’s Late Stage Product Pipeline
Figure 5-11: Genzyme’s Late Stage Product Pipeline by Therapeutic Area
Table 5-13: Biogen Idec’s Late Stage Product Pipeline
Figure 5-12: Biogen Idec’s Late Stage Product Pipeline by Therapeutic Area
Table 5-14: Hospira’s Late Stage Product Pipeline
Figure 5-13: Hospira’s Late Stage Product Pipeline by Therapeutic Area
Table 5-15: CSL’s Late Stage Product Pipeline
Figure 5-14: CSL’s Late Stage Product Pipeline by Therapeutic Area
Table 5-16: Alcon’s Late Stage Product Pipeline
Figure 5-15: Alcon’s Late Stage Product Pipeline by Therapeutic Area
Table 5-17: Shire’s Late Stage Product Pipeline
Figure 5-16: Shire’s Late Stage Product Pipeline by Therapeutic Area
Table 5-18: Celgene’s Late Stage Product Pipeline
Figure 5-17: Celgene’s Late Stage Product Pipeline by Therapeutic Area
Table 5-19: Lundbeck’s Late Stage Product Pipeline
Figure 5-18: Lundbeck’s Late Stage Product Pipeline by Therapeutic Area
Table 5-20: Shionogi’s Late Stage Product Pipeline
Figure 5-19: Shionogi’s Late Stage Product Pipeline by Therapeutic Area
Table 5-21: Menarini’s Late Stage Product Pipeline
Figure 5-20: Menarini’s Late Stage Product Pipeline by Therapeutic Area
Table 5-22: Dainippon Sumitomo’s Late Stage Product Pipeline
Figure 5-21: Dainippon Sumitomo’s Late Stage Product Pipeline by Therapeutic Area
Table 5-23: Cephalon’s Late Stage Product Pipeline
Figure 5-22: Cephalon’s Late Stage Product Pipeline by Therapeutic Area
Table 5-24: Actelion’s Late Stage Product Pipeline
Figure 5-23: Actelion’s Late Stage Product Pipeline by Therapeutic Area
Table 5-25: Endo Pharmaceutical’s Late Stage Product Pipeline
Figure 5-24: Endo Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
Table 5-26: Ono Pharmaceutical’s Late Stage Product Pipeline
Figure 5-25: Ono Pharmaceutical’s Late Stage Product Pipeline by Therapeutic Area
Table 5-27: Purdue Pharma’s Late Stage Product Pipeline
Figure 5-26: Purdue Pharma’s Late Stage Product Pipeline by Therapeutic Area

CHAPTER SIX: MARKET FORECAST
Table 6-1: Top Pharmaceutical Companies, 1-50 by 2009 Sales (millions)
Table 6-2: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20 Companies by Revenues)
Table 6-3: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
Figure 6-2: Company Pipelines by Total Late Stage Development Projects (Companies 21-50 by Revenues)
Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010 ($ in billions)
Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment 2005-2010
Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated ($ in billions)
Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—based on late stage development projects evaluated
Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2015—Potential Impact from Late-Stage Development
Figure 6-6: Global Pharmaceutical Market Forecast by, 2015—Potential Impact from Late-Stage Development

CHAPTER SEVEN: BIOPHARMACEUTICAL MARKET
Table 7-1: Top 10 Biotechnology Companies*, 2009 Sales
Table 7-2: Top 10 Biotechnology and Pharmaceutical Products, by 2009 Revenues
Table 7-3: Biotechnology Late Stage Development Projects by Company Classification—Pharmaceutical vs. Biotechnology--Market Forecast, 2015